Patents by Inventor Alejandro Amor-Coarasa
Alejandro Amor-Coarasa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240050599Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.Type: ApplicationFiled: February 23, 2023Publication date: February 15, 2024Applicant: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20230285603Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.Type: ApplicationFiled: October 11, 2022Publication date: September 14, 2023Applicant: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20230165979Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a non-small cell lung cancer, small cell carcinoma of the lung, bladder cancer, colon cancer, gallbladder cancer, pancreatic cancer, esophageal cancer, melanoma, liver cancer, primary gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, prostate cancer, a neuroendocrine tumor, a pituitary tumor, a vasoactive intestinal peptide-secreting tumor, a glioma, breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, and/or a metastatic cancer.Type: ApplicationFiled: April 14, 2021Publication date: June 1, 2023Applicants: Cornell University, The University of MelbourneInventors: John W. BABICH, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala, Paul Donnelly
-
Publication number: 20230114130Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 22, 2022Publication date: April 13, 2023Applicant: Comell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnaia
-
Patent number: 11497820Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.Type: GrantFiled: September 9, 2020Date of Patent: November 15, 2022Assignee: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20220194904Abstract: The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula I or a pharmaceutically acceptable salt thereof, wherein one of R1, R2, and R3 is and of Formula IV or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 30, 2021Publication date: June 23, 2022Applicant: Cornell UniversityInventors: John W. Babich, Jasmes M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Patent number: 11285227Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 5, 2018Date of Patent: March 29, 2022Assignee: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20210137860Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.Type: ApplicationFiled: June 19, 2020Publication date: May 13, 2021Applicant: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20210128757Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 5, 2018Publication date: May 6, 2021Applicant: CORNELL UNIVERSITYInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20210121584Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.Type: ApplicationFiled: December 23, 2020Publication date: April 29, 2021Applicant: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20200405888Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.Type: ApplicationFiled: September 9, 2020Publication date: December 31, 2020Applicant: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Patent number: 10806806Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.Type: GrantFiled: September 18, 2018Date of Patent: October 20, 2020Assignee: CORNELL UNIVERSITYInventors: John W. Babich, Alejandro Amor-Coarasa, James M. Kelly, Shashikanth Ponnala
-
Patent number: 10716772Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.Type: GrantFiled: January 11, 2019Date of Patent: July 21, 2020Assignee: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20190375720Abstract: The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula I or a pharmaceutically acceptable salt thereof, wherein one of R1, R2, and R3 is and of Formula IV or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 26, 2018Publication date: December 12, 2019Inventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20190142770Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.Type: ApplicationFiled: January 11, 2019Publication date: May 16, 2019Inventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20190015531Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.Type: ApplicationFiled: September 18, 2018Publication date: January 17, 2019Inventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Patent number: 10179117Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.Type: GrantFiled: June 22, 2017Date of Patent: January 15, 2019Assignee: Cornell UniversityInventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20170369454Abstract: The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula I or a pharmaceutically acceptable salt thereof, wherein one of R1, R2, and R3 is and of Formula IV or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 28, 2017Publication date: December 28, 2017Inventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
-
Publication number: 20170368005Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.Type: ApplicationFiled: June 22, 2017Publication date: December 28, 2017Inventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala